The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11068 malaria professionals are enjoying the free benefits of MalariaWorld today


Safety and Efficacy of Tafenoquine for Plasmodium vivax Malaria Prophylaxis and Radical Cure: Overview and Perspectives

September 14, 2021 - 14:17 -- Open Access
Markus MB
Therapeutics and Clinical Risk Management,Volume 17

This article is inter alia a brief, first-stop guide to possible adverse events (AEs) associated with tafenoquine (TQ) intake. Safety and efficacy findings for TQ in Plasmodium vivax malaria prophylaxis and radical cure are summarized and some of the latest TQ-related studies (published in 2020 and 2021) are highlighted.

Monthly Malaria Prophylaxis Cuts Child Deaths in Sub-Saharan Africa

January 20, 2021 - 06:58 -- Open Access
Kuehn BM
JAMA. 2021 Jan 19;325(3):213

Treating children in sub-Saharan Africa’s malaria-endemic areas with a monthly preventive drug regimen during the rainy season reduced children’s deaths from the disease by up to 57%, a study found.

Study protocol of a cluster randomized controlled trial of strategies to increase antenatal iron and folic acid supplementation and malaria prophylaxis in rural south-central Côte d'Ivoire

October 31, 2020 - 09:23 -- Open Access
Koné S, Utzinger J, Probst-Hensch N, Dao D, Fink G
BMC Public Health. 2020 Oct 27;20(1):1609

Coverage of antenatal iron and folic acid supplementation (IFAS) and intermittent preventive treatment of malaria in pregnancy (IPTp) remains low in many countries. Evidence on the most effective ways to increase both IFASIPTp is mixed overall, with only few studies directly identifying cost-effective ways to increase coverage of both interventions. The proposed study aims to assess the cost, impact and relative cost-effectiveness of two complementary strategies of increasing IFAS and malaria chemoprophylaxis coverage among pregnant women relative to the current default system in a rural low-income setting of sub-Saharan Africa.

Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness

October 7, 2020 - 16:11 -- Open Access
Al-Kofahi M, Jacobson P, Boulware DR, Matas A, Kandaswamy R, Jaber MM, Rajasingham R, Young JH, Nicol MR
Clin Pharmacol Ther. 2020 Oct;108(4):766-769

Hydroxychloroquine is an antimalarial drug being tested as a potential treatment for the novel coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2. Although the efficacy of hydroxychloroquine for COVID-19 remains uncertain, it may serve as a potential prophylactic agent especially in those at high risk, such as healthcare workers, household contacts of infected patients, and the immunocompromised.

NOT Open Access | Efficacy and Safety of a Naphthoquine-Azithromycin Co-Formulation for Malaria Prophylaxis in Southeast Asia: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial

July 21, 2020 - 15:13 -- NOT Open Access
Yang H, Wang J, Cui L, et al.
Clin Infect Dis. 2020 Jul 20:ciaa1018

A prophylactic antimalarial drug that is both effective for protection and improves compliance is in high demand.

Malaria prophylaxis approach during COVID-19 pandemic

May 6, 2020 - 14:58 -- Open Access
Rodriguez-Valero N, Vera I, Torralvo MR, De Alba T, Ferrer E, Camprubi D, Almuedo Riera A, Gallego RS, Muelas M, Pinazo MJ, Muñoz J
Travel Med Infect Dis. 2020 Apr 29:101716

Malaria drugs chloroquine and hydroxychloroquine are currently being evaluated in a number of clinical trials as active treatments against SARS-CoV-2 virus. They are also postulated for pre and postexposure prophylaxis for the prevention of COVID-19. It has been recently shown that both molecules inhibit in-vitro the entry of the virus in the cell, and they can stop the cytokine storm derived from the infection alongside impeding T cell activation [1,2]. In particular, hydroxychloroquine is a drug with an excellent safety profile, even for pregnant women. Furthermore, hydroxychloroquine has been successfully used during decades for the management of rheumatologic diseases modulating inflammation and organ damage [3].

NOT Open Access | Ivermectin for causal malaria prophylaxis: a randomised controlled human infection trial

March 9, 2020 - 13:32 -- Kabogo Ndegwa
Metzger WG, Theurer A, Pfleiderer A, Molnar Z, Maihöfer-Braatting D, Bissinger AL, Sulyok Z, Köhler C, Egger-Adam D, Lalremruata A, Esen M, Lee Sim K, Hoffman S, Rabinovich R, Chaccour C, Alonso P, Mordmüller BG, Kremsner PG
Tropical Medicine and International Health Volume 25, Issue 3, March 2020, Pages 380-386

Ivermectin is safe and widely used for treating helminth infections. It also kills arthropods feeding on treated subjects, including malaria vectors. Thus, ivermectin mass drug administration as an additional tool for malaria control is being evaluated by WHO. As in vitro data, animal experiments and epidemiological observations suggest that ivermectin has a direct effect on the liver stages of the malaria parasite, this study was designed to assess the prophylactic effect of ivermectin on Plasmodium falciparum controlled human malaria infection.

NOT Open Access | Mefloquine for malaria prophylaxis in military personnel

March 2, 2020 - 14:05 -- NOT Open Access
Williamson V, Blamey H, Sharpley J, David A, Greenberg N
BMJ Mil Health. 2020 Feb 20. pii: jramc-2019-001295

The British Army adopted mefloquine (Lariam) as its preferred drug for chemoprophylaxis against malaria in 1993. Treatment doses of mefloquine had already been reported to cause an acute brain syndrome. In 1996, army doctors reported a private soldier who, after six doses of mefloquine prophylaxis, saw the Grim Reaper standing behind the chaplain, heard incoherent voices, and was admitted to a psychiatric hospital; more reports followed.

Non-adherence to malaria prophylaxis: The influence of travel-related and psychosocial factors

November 12, 2019 - 15:59 -- Open Access
Jolanda G.M. Hoefnagel, Karlijn Massar, Jeannine L.A. Hautvast
Journal of Infection and Public Health, 6 November 2019

The effectiveness of malaria chemoprophylaxis is limited by a lack of compliance in travellers. This study assesses the demographic, travel-related, and psychosocial determinants of non-compliance with chemoprophylaxis.


Subscribe to RSS - prophylaxis